TABLE 1.
Summary of the ability of various anti-HIV-1 antibodies to inhibit the binding of 4KG5 scFv to gp120JR-FL
| Antibody identification | Antibody specificity | Effect of antibody (30 μg/ml) on 4KG5 binding to gp120JR-FLb |
|---|---|---|
| p35 | C1 (d)a | 0 |
| 522-149 | C1 (d) | 0 |
| G3-4 | V2 (d) | I ↓ |
| G3-136 | V2 (d) | I ↓ |
| 19b | V3 loop | I ↓↓↓ |
| 447-52D | V3 loop | I ↓↓↓ |
| hNM01 | V3 loop | I ↓↓ |
| AH48c | V3 loop | I ↓↓↓ |
| loop2 | V3 loop | I ↓↓↓ |
| F425 B4e8 | V3 loop | I ↓↓↓ |
| 694-88D | V3 loop | I ↓↓↓ |
| G3-299 | C4-V3 (d) | I ↓ |
| G3-42 | C4-V3 (d) | I ↓ |
| G3-519 | C4 | I ↓ |
| G3-537 | C4 | I ↓ |
| b12 | CD4bs | E ↑ |
| b6 | CD4bs | I ↓↓↓ |
| b3 | CD4bs | I ↓↓ |
| F91 | CD4bs | I ↓↓ |
| F105 | CD4bs | I ↓↓ |
| 15e | CD4bs | I ↓↓↓ |
| L33 | CD4bs | I ↓↓ |
| 1008-D | CD4bs | I ↓↓ |
| 654-30D | CD4bs | I ↓↓ |
| 559-64D | CD4bs | I ↓↓ |
| 1027-30D | CD4bs | I ↓↓ |
| Ia3c | CD4bs | I ↓↓ |
| Ia7c | CD4bs | I ↓↓ |
| FG39c | CD4bs | I ↓ |
| Fbb14c | CD4bs | 0 |
| sCD4 | true CD4bs | I ↓ |
| A32 | C1-C4 (CD4i) | 0 |
| 17b | CD4i | 0 |
| X5 | CD4i | 0 |
| 48d | CD4i | 0 |
| Fbb21c | CD4i | 0 |
| 2G12 | Carbohydrate (outer face) | 0 |
| 1C1 | C5 | 0 |
| M91 | C5 | 0 |
| 670-D | C5 | 0 |
| 1331A | C5 | 0 |
| D7324 | C5 (polyclonal) | 0 |
| KZ52 | Ebola group | 0 |
| FDA2 | Patient serum (polyclonal) | I ↓↓ |
| HIVIG | Pooled HIV-1+ human IgG (polyclonal) | I ↓↓ |
a
d, discontinuous (epitope).
b
4KG5 was used at a concentration previously determined to result in ∼75% maximal binding (∼0.3 μg/ml), and was detected via the hexahistidine tag by using the India-HIS probe reagent (Pierce). 0, 75 to 110% maximal binding (i.e., no effect); I, inhibition; ↓ 50 to 74% maximal binding; ↓↓, 25 to 49% maximal binding; ↓↓↓, <25% maximal binding; E, enhancement (emphasized with bold type); ↑, >130% maximal binding.
c
Novel human antibody identified in this study.